These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11577167)

  • 21. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
    Osin P; Crook T; Powles T; Peto J; Gusterson B
    Lancet; 1998 May; 351(9114):1487. PubMed ID: 9605807
    [No Abstract]   [Full Text] [Related]  

  • 22. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
    De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
    J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
    Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromosome 16q loss--a genetic key to the understanding of breast carcinogenesis.
    Bürger H; de Boer M; van Diest PJ; Korsching E
    Histol Histopathol; 2013 Mar; 28(3):311-20. PubMed ID: 23348384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases.
    Wagner PL; Kitabayashi N; Chen YT; Shin SJ
    Am J Clin Pathol; 2009 Dec; 132(6):871-6. PubMed ID: 19926578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
    Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
    J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.
    Yoder BJ; Wilkinson EJ; Massoll NA
    Breast J; 2007; 13(2):172-9. PubMed ID: 17319859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
    Gatalica Z; Lele SM; Rampy BA; Norris BA
    Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
    Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
    Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
    Lakhani SR; Gusterson BA; Jacquemier J; Sloane JP; Anderson TJ; van de Vijver MJ; Venter D; Freeman A; Antoniou A; McGuffog L; Smyth E; Steel CM; Haites N; Scott RJ; Goldgar D; Neuhausen S; Daly PA; Ormiston W; McManus R; Scherneck S; Ponder BA; Futreal PA; Peto J; Stoppa-Lyonnet D; Bignon YJ; Stratton MR
    Clin Cancer Res; 2000 Mar; 6(3):782-9. PubMed ID: 10741697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Atypical ductal and lobular hyperplasia of the breast].
    Bricou A; Delpech Y; Barranger E
    Gynecol Obstet Fertil; 2009 Oct; 37(10):814-9. PubMed ID: 19766043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
    Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
    Hanby AM; Kelsell DP; Potts HW; Gillett CE; Bishop DT; Spurr NK; Barnes DM
    Int J Cancer; 2000 Oct; 88(2):204-8. PubMed ID: 11004669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction.
    Rueth NM; McMahon M; Arrington AK; Swenson K; Leach J; Tuttle TM
    Ann Surg Oncol; 2011 Sep; 18(9):2515-20. PubMed ID: 21424371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of c-kit in common benign and malignant breast lesions.
    Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
    Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.